OKYO Pharma (OKYO) grants CMO 20,000 common shares
Rhea-AI Filing Summary
Mantelli Flavio reported acquisition or exercise transactions in this Form 4 filing.
OKYO Pharma Ltd’s chief medical officer, Flavio Mantelli, received a grant of 20,000 shares of common stock on July 21, 2026. The award was recorded at $1.40 per share as direct ownership, and Mantelli now directly holds 20,000 shares of OKYO Pharma common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 20,000 shares
Net Buy
1 txn
Insider
Mantelli Flavio
Role
CHIEF MEDICAL OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | COMMON STOCK | 20,000 | $1.40 | $28K |
Holdings After Transaction:
COMMON STOCK — 20,000 shares (Direct)
Key Figures
Shares granted: 20,000 shares of common stock
Grant price: $1.40 per share
Post-transaction holdings: 20,000 shares
3 metrics
Shares granted
20,000 shares of common stock
Grant, award, or other acquisition on July 21, 2026
Grant price
$1.40 per share
Recorded transaction price for the 20,000-share award
Post-transaction holdings
20,000 shares
Total common shares directly owned by Flavio Mantelli after the grant
Key Terms
Grant, award, or other acquisition, COMMON STOCK
2 terms
Grant, award, or other acquisition regulatory
"transaction_code_description: Grant, award, or other acquisition"
COMMON STOCK financial
"security_title: COMMON STOCK reported as non-derivative"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did OKYO (OKYO) report for Flavio Mantelli?
OKYO Pharma reported that chief medical officer Flavio Mantelli received a grant of 20,000 shares of common stock. The transaction was recorded as a grant, award, or other acquisition on July 21, 2026, and is held as direct ownership.
What is Flavio Mantelli’s ownership in OKYO (OKYO) after this grant?
Following the grant, Flavio Mantelli directly owns 20,000 shares of OKYO Pharma common stock. The Form 4 transaction report shows total shares following the transaction equal to 20,000, all classified as directly held.
What type of Form 4 transaction was filed for OKYO (OKYO)?
The transaction for OKYO Pharma was reported as a grant, award, or other acquisition of common stock. It is coded as an acquisition (Code A) of non-derivative securities rather than a market purchase or sale of existing shares.
Is the OKYO (OKYO) Form 4 transaction a derivative exercise or a stock award?
The Form 4 shows a stock award, not a derivative exercise. It involves 20,000 shares of common stock classified as a non-derivative security, with no exercise price, exercise date, or expiration date associated with options or other derivatives.